Eliana Merle
#268 out of 1697 analysts
Barclays
Automatically Tracked
Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
Gain and growth charts are calculated per selected timeframe:
39.5%
Gain +0.04%
Monthly
-0.86%
Yearly
-9.84%
Drawdown
77.7%
$55,965.81
Equity
Holdings
$15,989.01
Cash
$39,976.8
Investment
$19,156.84
-$57,127.31
Profit +$20.62
Realized
-$53,959.47
Unrealized
-$3,167.83
Dividends
$122.59
$39,976.8
Cash
Deposits
$113,093.12
Withdrawals
$0
Commissions
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0.04%
Profit
$20.62
Win %
3%
This Week
Compared To Last Week
Gain
-0.24%
Profit
-$134.83
Win %
3%
This Month
Compared to last month
Gain
-4.08%
Profit
-$2,379.42
Win %
3%
This Year
Compared to last year
Gain
12.47%
Profit
$6,206.49
Win %
63%
ALNY Alnylam Pharmaceuticals Inc
+3.17%
+$48.22 
INSM Insmed Inc.
+2.02%
+$28.24 
IONS Ionis Pharmaceuticals, Inc.
+1.94%
+$22.15 
ASND Ascendis Pharma A/S
+0.86%
+$12.93 
MDGL Madrigal Pharmaceuticals, Inc.
+0.86%
+$12.78 
PTCT PTC Therapeutics, Inc.
+0.8%
+$11.62 
RARE Ultragenyx Pharmaceutical Inc.
+0.62%
+$5.61 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 713 | Longs Won 291/684 42% | Profit Factor 0.57 |
| Profitability | Shorts Won 20/29 68% | Standard Deviation $1,420.73 |
| Average Win $245.56 | Best Trade (Dec 07) $7,304.88 | Sharpe Ratio -305.73 |
| Average Loss -$333.23 | Worst Trade (Mar 17) -$21,274.35 | Z-Score -8.32 (100%) |
| Commissions $0 | Avg. Trade Length 1m 2w 4d | Expectancy -$80.12 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 168 | 151 | 134 | 118 | 101 | 84 | 67 | 50 | 34 | 17 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals Inc | 6.92 | $1,556.02 | $1,569.48 | - | $13.46 | 0.87% | +3.17% |
| ASND Ascendis Pharma A/S | 6.56 | $1,672.21 | $1,509.53 | - | -$162.68 | -9.73% | +0.864% |
 BMRN Biomarin Pharmaceutical Inc. | 25.07 | $1,668.19 | $1,422.4 | - | -$245.79 | -14.73% | -1.382% |
| INSM Insmed Inc. | 13.48 | $1,538.84 | $1,428.09 | - | -$110.75 | -7.2% | +2.018% |
| IONS Ionis Pharmaceuticals, Inc. | 26.21 | $1,523.08 | $1,162.49 | - | -$360.59 | -23.68% | +1.943% |
 KYMR Kymera Therapeutics Inc. | 13.61 | $1,561.65 | $1,440.78 | - | -$120.87 | -7.74% | -3.646% |
| MDGL Madrigal Pharmaceuticals, Inc. | 3.01 | $1,610.54 | $1,498.65 | - | -$111.89 | -6.95% | +0.86% |
| PTCT PTC Therapeutics, Inc. | 22.79 | $1,631.9 | $1,462.24 | - | -$169.66 | -10.4% | +0.801% |
 QURE uniQure N.V. | 33.02 | $1,500.76 | $734.75 | - | -$766.01 | -51.04% | -2.412% |
| RARE Ultragenyx Pharmaceutical Inc. | 62.32 | $1,662.23 | $909.28 | - | -$752.95 | -45.3% | +0.621% |
 SGMT Sagimet Biosciences Inc. | 152.24 | $1,653.33 | $1,347.33 | - | -$306 | -18.51% | -1.993% |
 VRTX Vertex Pharmaceuticals Incorporated | 2.99 | $1,578.1 | $1,504 | - | -$74.1 | -4.7% | -0.062% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
2026 © Marketlog. All Rights Reserved.
